| Document |
Document Title |
|
WO/2019/108033A1 |
The present specification provides a compound represented by chemical formula 1, and an organic light emitting element comprising the same.
|
|
WO/2019/101059A1 |
A compound having the structure shown in formula I, a liquid crystal composition comprising the compound having the structure shown in formula I, and an electro-optical display device comprising the liquid crystal composition. The compou...
|
|
WO/2019/099457A1 |
Provided herein are benzodioxinone compounds of Formula I that are useful as inhibitors of ACC1 and/or ACC2. The benzodioxinone compounds described herein can be used for treating a disease or disorder associated with aberrant ACC1 and/o...
|
|
WO/2019/090085A1 |
Provided herein are compounds of formula (I), compositions, and methods useful for modulating the integrated stress response (ISR) and for treating related diseases, disorders and conditions. (Formula I).
|
|
WO/2019/082209A1 |
The present invention related to stable N-((1R, 2R)-1-(2,3-dihydrobenzo[b][1,4] dioxin-6-yl)- 1-hydroxy-3- (pyrrolidin-1-yl)propan-2-yl) octanamide (2R,3R)- 2,3-dihydroxysuccinate premix of formula (Ia) and its process for preparation th...
|
|
WO/2019/078462A1 |
The present invention provides a novel heterocyclic compound and an organic light-emitting device using same.
|
|
WO/2019/076343A1 |
Disclosed are a PD-1/PD-L1 small-molecule inhibitor and a preparation method therefor and use thereof. In particular, disclosed are a compound which has a structure as shown in formula L, a stereoisomer or a tautomer thereof, or a pharma...
|
|
WO/2019/078443A1 |
The present invention provides a novel compound and an organic light emitting device using the same.
|
|
WO/2019/075195A1 |
The present disclosure provides processes for preparing (+)-pleuromutilin and synthetic (+)-pleuromutilin produced therefrom. Also provided are intermediates prepared thereby and processes for preparing these intermediates.
|
|
WO/2019/067543A1 |
The present disclosure relates to compounds that are capable penetrating to the blood brain barrier to modulate the activity of EGFR tyrosine kinase. The disclosure further relates to methods of treating Glioblastoma and other EGFR media...
|
|
WO/2019/054634A1 |
The present invention provides a novel heterocyclic compound and an organic light-emitting device using same.
|
|
WO/2019/043610A1 |
The present invention relates to novel heterocyclic compounds of the general formula (I) their pharmaceutically acceptable salts, pharmaceutically acceptable solvates, enantiomers, diastereomers and polymorphs. The invention also relates...
|
|
WO/2019/039290A1 |
Provided are: an actinic ray-sensitive or radiation-sensitive resin composition that has excellent resolution, exposure latitude, and pattern shape properties; and a resist film, a pattern-forming method, a method for producing an electr...
|
|
WO/2019/037862A1 |
The invention relates to organosulphur compounds which can be obtained from rose oxide, to methods for producing said organosulphur compounds and their use as odorants, flavourings or constituents of odorant mixtures and the products der...
|
|
WO/2019/032126A1 |
Processes for preparing heteroatom containing cyclic dimers that result in increased production efficiency and reduced waste production.
|
|
WO/2019/014748A1 |
Methods for prevention and treatment of asthma attacks involve the administration of one or more TRPV1 antagonists, one or more LPAr antagonists or preferably a combination of one or more TRPV1 antagonists and one or more LPAr antagonist...
|
|
WO/2019/009956A1 |
Provided herein are methods for preparing ketone-containing organic molecules. The methods are based on novel iron/copper-mediated ("Fe/Cu-mediated") coupling reactions. The Fe/Cu-mediated coupling reaction can be used in the preparation...
|
|
WO/2018/236913A1 |
Small molecule calpain modulator compositions and pharmaceutical compositions can be prepared and used as therapeutic agents. Exemplary compositions include non-macrocyclic a-keto amide derivatives. The therarapeutic agents can be used f...
|
|
WO/2018/230322A1 |
The compound of the present invention is represented by formula (i), in particular, represented by formula (i) in which Ki1 has a structure represented by any of formulae (K-1) to (K-3). This compound, when used in a liquid-crystal compo...
|
|
WO/2018/225018A1 |
The present invention relates to novel heterocyclic compounds of the general formula (I) their pharmaceutically acceptable salts, pharmaceutically acceptable solvates, enantiomers, diastereomers and polymorphs. The invention also relates...
|
|
WO/2018/220020A2 |
The invention relates to resorcinol-derived compounds of formula (I) and also the salts thereof, the solvates thereof and the optical and/or geometrical isomers thereof, including enantiomers and diastereoisomers, the racemic mixtures th...
|
|
WO/2018/222444A1 |
Embodiments of the disclosure relate to methods of selectively depositing organic and hybrid organic/inorganic layers. More particularly, embodiments of the disclosure are directed to methods of modifying hydroxyl terminated surfaces for...
|
|
WO/2018/212463A1 |
The present invention relates to a novel compound and an organic electroluminescent element including the same. According to the present invention, the compound is used for an organic layer of the organic electroluminescent element, pref...
|
|
WO/2018/193090A2 |
Process for preparation of eliglustat hemitartrate and intermediates thereof Processes for preparation of eliglustat hemitartrate and intermediates thereof are provided. A stable amorphous form of eliglustat hemitartrate pharmaceutical c...
|
|
WO/2018/176884A1 |
Disclosed is a method for producing optically pure L-/D-lactide with an all-green closed cycle process, with an aqueous L-/D-lactic acid solution and polylactic acid, which is produced as a by-product, being used as raw materials, wherei...
|
|
WO/2018/172423A1 |
The invention relates to a compound which is an indane derivative according to Formula (I), or a pharmaceutically acceptable salt thereof, [FORMULA (I)] wherein R1, R2, R3, n, R4, p¸ q, L, ׇ, X and m are as defined herein. The compound...
|
|
WO/2018/171942A1 |
It is disclosed a process for obtaining phenolic derivatives with high industrial interest in the pharmaceutical industry by using glycerol carbonate. Specifically, the process provides for a phenol substituted in position 2 to react wit...
|
|
WO/2018/171173A1 |
The present invention relates to a method for synthesis of Eliglustat and intermediate compounds thereof. Specifically, the present invention relates to the field of synthesis of organic compounds, to a method for synthesis of Eliglustat...
|
|
WO/2018/167800A1 |
The present invention relates to fused bicyclic compounds that are inhibitors of GPR91, their stereoisomers, tautomers, prodrugs, polymorphs, solvates, pharmaceutically acceptable salts, and pharmaceutical compositions containing them. T...
|
|
WO/2018/167143A1 |
A process for preparing a cyclic diester or a cyclic diamide by reacting a hydroxycarboxylic acid or amide with an acidic BEA (H-beta polymorph A) type zeolite. The process is characterised in that the total amount of acid sites is in th...
|
|
WO/2018/154519A1 |
The present invention relates to compounds and their use in the treatment of cystic fibrosis, methods for their production, pharmaceutical compositions comprising the same, and methods of treating cystic fibrosis by administering a compo...
|
|
WO/2018/154493A1 |
The present invention relates to compounds and their use in the treatment of cystic fibrosis, methods for their production, pharmaceutical compositions comprising the same, and methods of treating cystic fibrosis by administering a compo...
|
|
WO/2018/157043A1 |
Disclosed are oxazolidinone compounds of Formula I: (I) salts thereof, antibacterial pharmaceutical compositions containing them, and use of the compounds to inhibit bacterial growth in mammals, including humans.
|
|
WO/2018/141759A1 |
The invention relates to compounds of formula (I), wherein R1, L1, L2 and X have the meanings defined in claim 1, to a method for the production thereof, to liquid-crystalline media containing at least one compound of formula (I), and to...
|
|
WO/2018/140738A1 |
Provided are compounds of Formula I, or pharmaceutically acceptable salts thereof, which are activators of nuclear factor erythroid 2 (NF-E2) -related factor 2 (Nrf2) and are useful to treat diseases caused by oxidative stress, such as n...
|
|
WO/2018/139107A1 |
Provided is a method for producing a high-purity α-hydroxycarboxylic acid dimer cyclic ester while preventing α-hydroxycarboxylic acid oligomers from becoming heavy. The α-hydroxycarboxylic acid dimer cyclic ester is obtained by carry...
|
|
WO/2018/124148A1 |
The purpose of the present invention relates to providing a novel glyceric acid ester which can be produced at a high yield and for which use as a synthesis intermediate can be expected, and a method for producing same. The purpose of th...
|
|
WO/2018/124149A1 |
The purpose of the present invention is to provide a method for producing glyceric acid ester that enables easy, high-yield production and makes it easy to reuse pyridines that are used for a reaction. Provided is a method for producing ...
|
|
WO/2018/124147A1 |
The present invention relates to a method for manufacturing 1,3-dioxane-5-ones by a short and simple method from raw materials that can be obtained easily and inexpensively, using 1,3-dioxane, which is a mixture with 1,3-dioxalans, as a ...
|
|
WO/2018/109714A2 |
Bis-cyclic carbonate molecule consisting of at least two (l,3)-dioxine-2-one structures directly linked to each other or indirectly linked via other cycles.
|
|
WO/2018/105237A1 |
A novel method for producing a trioxopropane compound is provided. The present invention provides a method for producing a trioxopropane compound represented by general formula (1), the method being characterized by reacting a dioxopropa...
|
|
WO/2018/100016A1 |
The present invention relates to 1-fluorocyclohexyl-methoxy-aryl compounds of formula (I), in which R1, R2, A1, A2, m and n are defined as indicated in claim 1, to their production, to their use as components in liquid crystal media and ...
|
|
WO/2018/100515A1 |
The invention relates to novel ruthenium complexes of formula (9). The invention also relates to the method for preparation of novel metal complexes of formula (9) and their use in olefin metathesis reactions.
|
|
WO/2018/087126A1 |
The present invention relates to amido-substituted cyclohexane compounds of general formula (I), in which A, R4, R6, R7, R8, R9, R10 and R11 are as defined herein, to methods of preparing said compounds, to intermediate compounds useful ...
|
|
WO/2018/088182A1 |
A method for recovering lactide, the method comprising holding a lactide-containing resin mixture at a reduced pressure to gasify the lactide contained in the resin mixture, introducing, with evacuation, a gas mixture including the resul...
|
|
WO/2018/079333A1 |
The present invention provides a spontaneous alignment assistant for liquid crystal compositions, which is capable of ensuring storage stability if added to a liquid crystal composition, while enabling vertical alignment of liquid crysta...
|
|
WO/2018/075275A1 |
Disclosed are of the protected photoinitiators of the formula: wherein Aryl1 is an aromatic or heteroaromatic ring; Aryl2 is an aromatic ring; each R1 is an alkyl, an aryl, an electron donating group or an electron withdrawing group, and...
|
|
WO/2018/065387A1 |
The present invention relates to hamamelitannin analogues, pharmaceutical compositions comprising the same, and combinations thereof with anti-microbial agents such as antibiotics or disinfectants. It in particular relates to the use of ...
|
|
WO/2018/059372A1 |
The present invention relates to a group of derivatives synthesized based on the ent-kaurane diterpenoid flexicaulin A and the methods to synthesize such diterpenoid derivatives. In particular, the chemical entities of such synthetic dit...
|
|
WO/2018/062729A1 |
The present invention relates to a pseudo-ceramide compound and a preparation method therefor. According to the present invention, the pseudo-ceramide compound has a molecular structure and a function similar to those of a natural cerami...
|
